NeurogesX (NGSX) Falls After FDA Briefing Documents
Tweet
Share
E-mailGet Alerts NGSX Hot Sheet
Join SI Premium – FREE
NeurogesX, Inc. (Nasdaq: NGSX) is seeing pressure as FDA briefing documents are posted. Link
Comments look negative.
Shares last traded at $0.91, down 21%.
Comments look negative.
Shares last traded at $0.91, down 21%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Holcim said to acquire part of James Hardie's EU business
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
